CS3002

CS3002 is a highly selective, orally bioavailable small molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), developed by CStone Pharmaceuticals. It induces cell cycle arrest in tumor cells by directly inhibiting CDK4/6 kinase activities, thereby exhibiting potential antineoplastic activity. Preclinical studies have shown that CS3002's efficacy is comparable to palbociclib, an approved CDK4/6 inhibitor. In mouse models, CS3002 demonstrated enhanced anti-tumor effects when combined with anti-PD-1 monoclonal antibody therapy or endocrine therapy compared to monotherapies. A Phase I clinical trial has commenced in Australia, and the investigational new drug (IND) application has been approved in China for further development in oncology indications[1][2][3].

Other names

cs3002cs-3002cs 3002